

## Endothelin Increases Intracellular Free Calcium in Isolated Rat Nephron

Seok Ho Cha<sup>1</sup>, Young-Jin Cho<sup>2</sup>, Kweon-Haeng Lee<sup>2</sup>, and Hitoshi Endou<sup>1</sup>

<sup>1</sup>Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo 181, Japan; <sup>2</sup>Department of Pharmacology, Catholic University Medical College, Banpo-dong 505, Seocho-gu, Seoul 137–701, Korea

In the freshly isolated rat nephron, the effect of endothelin-1, -2 and -3 (ET-1, -2 and -3) on cytosolic free calcium concentration ( $[Ca^{2+}]_i$ ) was determined using the fluorescent indicator Fura-2/AM.  $[Ca^{2+}]_i$  increase was investigated in 9 parts of the single nephron including glomerulus (Glm), S<sub>1</sub>, S<sub>2</sub>, S<sub>3</sub>, cortical and medullary thick ascending limb and cortical (CCT) and outer medullary collecting tubule (OMCT). Endothelins increased  $[Ca^{2+}]_i$  in Glm (ET-1;  $127 \pm 17\%$ , ET-2;  $93 \pm 5\%$ , ET-3;  $169 \pm 17\%$ ), CCT (ET-1;  $30 \pm 6\%$ , ET-2;  $38 \pm 19\%$ , ET-3;  $158 \pm 18\%$ ) and OMCT (ET-1;  $197 \pm 11\%$ , ET-2;  $195 \pm 11\%$ , ET-3;  $215 \pm 37\%$ ) at  $10^{-7}$  M. In OMCT, ET-1 and ET-2 increased  $[Ca^{2+}]_i$  in a dose-dependent manner ( $10^{-10} \sim 10^{-6}$  M). To the contrary, ET-3-induced  $[Ca^{2+}]_i$  rise was begun from  $10^{-12}$  M. BQ-123Na, an antagonist of ET<sub>A</sub> receptor, at  $10^{-4}$  M inhibited about 30% of  $[Ca^{2+}]_i$  rise induced by ET-1 and -3. Binding experiments using [<sup>125</sup>I]ET-3 showed the existence of ET<sub>B</sub> receptor in OMCT. This binding was replaced by ET-1, ET-2 or ET-3 by the almost same degree but not by angiotensin II or vasopressin.

**Key Words:** Endothelin, Intracellular free calcium, Outer medullary collecting tubule

### INTRODUCTION

A vasoactive peptide, endothelin is a potent vasoconstrictor peptide originally characterized from the culture supernatant of porcine aortic endothelial cells consisting of 21 amino acid residues containing two sets of intrachain disulfide linkages (Yanagisawa et al, 1988). Some investigators reported that ET was produced in not only vascular endothelial cells, but also kidney, neural cells and epithelial cells (Yanagisawa et al, 1988, Giaid et al, 1989, Yoshizawa et al, 1990, Yoshimi et al, 1989).

Analysis of a human genomic library has led to the identification of three iso-peptides of ETs, designated ET-1, ET-2 and ET-3 (Yanagisawa et al, 1988, Inoue et al, 1989). In human endothelins, the structural

differences of ET-2 and ET-3 from that of ET-1 were 2 and 6 amino acid residue sequences, respectively. And their genes appeared to be present in the rat, porcine and human genome. Animal experiments, mainly on rats, have shown that the kidney vasculature was one of the vascular beds most sensitive to endothelin (Masaki 1989, Tomobe et al, 1988). Endothelin induced water and sodium excretion in concentration not causing GFR decrease (King et al, 1989). In addition to its action on vascular cells, ET has been reported to bind to and act upon epithelial cells (Totsune et al, 1989). The peptide apparently inhibits Na<sup>+</sup>-K<sup>+</sup>-ATPase in isolated epithelial cells of the inner medullary collecting tubules of rabbit (Zeidel et al, 1989). And endothelin has been known to increase cytosolic free calcium in target cells, e.g. blood vessels, smooth muscle cells and renal epithelial cells, which is mediated by the activation of inositol triphosphate (Vogel et al, 1977, Sugiura et al, 1989, Ankorima-Stark et al, 1997, Marsden et al, 1989, Naruse et al, 1991).

Corresponding to: Hitoshi Endou, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo 181, Japan, (Tel) +81-422-47-5511 ext) 3451, (Fax) +81-422-79-1321

Many papers have been published on the cells exhibiting the  $ET_A$  and  $ET_B$  type receptors (Martin et al, 1990, Sakurai et al, 1990, Arai et al, 1990, Ogawa et al, 1991). Recently, Samson et al, (1990) reported existence of an isoform receptor in cultured anterior pituitary cells which acted stronger at ET-3 than ET-1. This receptor was called  $ET_C$ -type receptor which did not become clear.

In the present study, therefore, we examined the effects of ET-1, -2 and -3 on transient  $[Ca^{2+}]_i$  and distribution of endothelins receptor subtypes in nephron segments freshly isolated from rat kidneys.

## METHODS

### Animals

Male Sprague-Dawley rats weighing 200~240 g were purchased from Saitama Experimental Laboratories (Saitama, Japan) and housed in commercial equipment in a conventional environment for at least 3 days prior to use. They were provided pelleted standard diet (Oriental Yeast, Osaka, Japan) and tap water *ad libitum*.

### Materials

The materials used were purchased as following: Fura-2/AM from Dojin Laboratories (Japan); ET-1, -2, -3 and angiotensin II from Peptide Institute Inc. (Japan); [ $^{125}I$ ] ET-3 from Amersham (Japan); aprotinin, bacitracin, N-ethylmaleimide, verapamil, 8-(N, N-diethyl-amino)octyl-3,4,5-trimethoxy-benzoate (TMB-8), vasopressin and collagenase from Sigma (USA); 8-hydroxyquinoline from Aldrich (USA); BQ-123Na was kindly donated by Dr. F. Ikemoto of Banyu Pharmaceutical Co., Ltd. (Japan). All other chemicals were of the highest grade available.

### Preparation of nephron segments

Microdissection techniques of various nephron segments have been previously described (Jung et al, 1989). Briefly, male Sprague-Dawley rats were decapitated, and left kidneys were perfused with modified Hanks' solution containing (in mM): NaCl, 127;  $MgSO_4$ , 0.8;  $Na_2HPO_4$ , 0.33;  $KH_2PO_4$ , 0.44;  $MgCl_2$ , 1;  $CH_3COONa$ , 10; Trizma base, 10;  $CaCl_2$ , 1 (pH

7.4) containing 2 mM pyruvate, 2 mM aspartic acid, 2 mM glutamic acid, 0.1% (wt/vol) bovine serum albumin (BSA) and 0.1% (wt/vol) collagenase (type I, 240 U/mg). Perfused kidneys were removed, and cut with 1mm thickness on the corticomedullary axis. The collagenase treatment was carried out at 37°C for 20 min with same solution. Microdissection of nephron segments was carried out at 4°C with fine siliconized stainless steel needle. The length of each nephron segments were measured with an ocular micrometer. The nephron segments were identified as previously reported (Kriz & Bankir 1988). The early proximal tubule ( $S_1$ ) was identified by its attachment to a glomerulus (Glm). The second portion of the proximal tubule ( $S_2$ ) was the transitional part of convolution to the straight portion. The late proximal tubule ( $S_3$ ) was identified by its attachment to the thin descending limb of Henle's loop. The medullary (MTAL) thick ascending limbs of Henle's loop was dissected from the inner stripe of the outer medulla. The distal tubule including connecting tubule was identified by its attachment to Glm. The cortical and medullary collecting tubules (CCT and OMCT) were dissected from the medullary ray of the cortex and the inner stripe of outer medulla, respectively.

The methods for  $[Ca^{2+}]_i$  measurement have been previously described (Cha et al, 1995, Jung & Endou 1990, Gryniewicz et al, 1985). Briefly, isolated nephron segments placed on the center of a serological glass were incubated at 25°C for 20 min with modified Hanks' solution containing 10  $\mu M$  Fura-2/AM, 10 mM  $CH_3COONa$ , 2 mM pyruvate, 2 mM aspartic acid, 2 mM glutamic acid, 10% fetal bovine serum (FCS) and 0.5 mM  $CaCl_2$  (pH 7.40) on a vibratile stage for histological immunostaining instruments. Fluorescence-loaded cells were washed three times with the same solution for exception of Fura-2/AM and FCS. The fluorescence loaded tubules together with 90  $\mu l$  medium were transferred on a cover glass siliconized freshly, and the fluorescence of a nephron segment was measured at 25°C using a 2 wave-length microscopic fluorometer (CAM 220, JASCO, Japan). During monitoring fluorescence intensity at two wave length, agonists or antagonists (10  $\mu l$ ) were mixed with the 90  $\mu l$  medium. In each nephron segment, the iris of fluorescence was maximally adjusted to each nephron diameter. Fluorescence emission at 510 nm was measured in response to excitation at 340 nm (F340) and 380 nm (F380),

and intracellular calcium concentrations were determined using the following formula:

$$[Ca^{2+}]_i = [(R-R_{min})/R_{max}-R] \times B \times 224$$

where R is the ratio F340/F380, R<sub>min</sub> is a ratio in the absence of calcium and R<sub>max</sub> is a ratio in the presence of an excess of calcium, and B is determined by the ratio of F380 in the absence of calcium to F380 in the presence of an excessive calcium.

#### Binding experiments of [<sup>125</sup>I] ET-3 to nephron segments.

[<sup>125</sup>I] ET-3 binding to OMCT was carried out principally by the method of Butlen et al, (1988) with a slight modification. Kidney slices were rinsed with dissection medium consisting of (in a final concentration in mM) NaCl, 137; KCl, 5; MgSO<sub>4</sub>, 0.8; Na<sub>2</sub>HPO<sub>4</sub>, 0.33; NaH<sub>2</sub>PO<sub>4</sub>, 0.44; NaHCO<sub>3</sub>, 4; MgCl<sub>2</sub>, 1; glucose, 5; CH<sub>3</sub>COONa, 10; CaCl<sub>2</sub>, 1; HEPES-NaOH, 20 (pH 7.40); containing 2 mM pyruvate, 2 mM aspartic acid, 2 mM glutamic acid, 0.1% (wt/vol) bovine serum albumin (BSA) and 3% dextran (molecular weight 40,000) and nephron segments were dissected. The 5 mm of tubules were incubated for 1 hr at 25°C in a 3 µl droplet of microdissection medium complemented with 0.05% aprotinin, 0.1%


bacitracin, 1 mM N-ethylmaleimide, 1 mM 8-hydroxyquinoline, and 200 pM of [<sup>125</sup>I] ET-3 and with (nonspecific binding) or without (total binding) 10<sup>-7</sup> M of unlabeled ET-1 or ET-3. The incubation was terminated by adding 200 µl of chilled microdissection medium. An 1 µl droplet containing the nephron segments was aspirated and washed twice with 200 µl of medium. Finally, the nephron segments in 1 µl droplet was transferred and radioactivity was counted using a gamma spectrometer (ARC-300, Aloka, Japan). Specific binding was calculated as the difference between total binding and nonspecific binding.

#### Statistics

All results are means ± SE. Student's *t* test was used for statistical comparisons between two groups.

## RESULTS

To define the effects of endothelins on intracellular free calcium in isolated rat nephron segments, we utilized calcium-sensitive fluorescent indicator, Fura-




**Fig. 1.** Representative signalings of effects of ET-1, -2 and -3 on intracellular free calcium concentration in isolated rat Glm and OMCT. The concentration of ETs was 10<sup>-6</sup> M.


**Table 1.** Effects of ET-1, -2 and -3 on  $[Ca^{2+}]_i$  of isolated rat single-nephron segments

	increasing% of basal $[Ca^{2+}]_i$			
	Glm	S <sub>1</sub>	S <sub>2</sub>	S <sub>3</sub>
ET-1	127 ± 17.2**	N.C.	N.C.	N.C.
ET-2	93 ± 17.2**	N.C.	N.C.	N.C.
ET-3	169 ± 17.2**	N.C.	N.C.	N.C.
	MTAL	DCT	CCT	OMCT
ET-1	N.C.	N.C.	30 ± 6*	197 ± 11**
ET-2	N.C.	N.C.	38 ± 19*	195 ± 11**
ET-3	N.C.	N.C.	158 ± 18**	215 ± 36**


Values are means ± SE. of 4 experiments. ET, endothelin; Glm, glomerulus; S<sub>1</sub>, early proximal tubule; S<sub>2</sub>, transitional part of convolution to the straight portion; S<sub>3</sub>, late proximal tubule; MTAL, medullary portion of thick ascending limb of Henle; DCT, distal convoluted tubule; CCT, cortical collecting tubule; OMCT, outer medullary collecting tubule. \*:p < 0.05, \*\*:p < 0.01 vs. resting  $[Ca^{2+}]_i$ .



**Fig. 2.** Representative signalings of effects of verapamil or TMB-8 on ET-3-induced  $[Ca^{2+}]_i$  transients in isolated rat Glm. Verapamil or TMB-8 were pretreated for 4 min or TMB-8 for 30 min, respectively.



**Fig. 3.** Dose-response curves of ET-1, -2 and -3 on  $[Ca^{2+}]_i$  transients in isolated rat OMCT. Highest  $[Ca^{2+}]_i$  peaks of each responses were calculated vs. basal  $[Ca^{2+}]_i$ . Values were presented mean  $\pm$  SE. of 6~9 experiments.




**Fig. 4.** Representative signalings of repeated effect and cross desensitization of ET-1 and/or ET-3. The concentration of endothelins was  $10^{-6}$  M.

2/AM. Fig. 1 shows typical signalings of ET-1-, ET-2- and ET-3-induced  $[Ca^{2+}]_i$  in Glm and OMCT. The patterns of changes in OMCT by ET-1, -2 and -3 ( $10^{-7}$  M) in fura-2 fluorescence were similar in other segments responded. ETs increased fluorescence intensity rapidly to a peak within 20 sec, followed by a fall to a steady level within 3~10 minutes.


From the fluorescence changes responsible to ET-1, -2 and -3, the responsiveness to endothelins along the nephron of rats is summarized in Table 1. The order of transient increase by ET-1, ET-2 and ET-3 were OMCT > Glm > CCT. The other segments had

no responsiveness to endothelins.

In order to assess a possible source of endothelin-induced  $[Ca^{2+}]_i$  increase, Glm was tested. Characteristically typical tracings peak in Glm show ET-3-induced  $[Ca^{2+}]_i$  to be biphasic, a rapid transient peak and a long sustained phase (Fig. 2).  $3 \times 10^{-5}$  M of verapamil, a calcium channel blocker, and  $10^{-4}$  M of TMB-8, a calcium release inhibitor from intracellular calcium pool, were utilized for ET-3-induced  $[Ca^{2+}]_i$ . In presence of verapamil, a rapid transient phase did not change but a sustained phase was inhibited slightly. And a rapid transient phase was inhibited by the pretreatment of TMB-8 for 30 min. Similar results



**Fig. 5.** Antagonistic effect of BQ-123Na in isolated rat OMCT.  
 a) Representative signalings of effect of BQ-123Na on ET-1- or ET-3-induced  $[Ca^{2+}]_i$ .  
 b) Summarization of effect of BQ-123Na on ET-1- or ET-3-induced  $[Ca^{2+}]_i$ .  
 Values are expressed mean  $\pm$  SE. of 5 rats.



**Fig. 6.** Competitive inhibitory effects of ET-1, -2, -3, ANG II and AVP in isolated rat OMCT. Binding experiment was performed with unlabelled agonists ( $10^{-7}M$ ) and  $[^{125}I]ET-3$  (200 pM). Values were expressed mean  $\pm$  SE (N=4).

obtained in OMCT, too (data were not shown).

Fig. 3 depicts the dose-response of endothelins in isolated rat OMCT. Each  $[Ca^{2+}]_i$  peak vs. basal  $[Ca^{2+}]_i$  was calculated. ET-1 and -2 increased  $[Ca^{2+}]_i$  in a dose-dependent manner from  $10^{-10}$  to  $10^{-6}$  M. On the other hand, ET-3-induced  $[Ca^{2+}]_i$  increase began at  $10^{-12}$  M.

Next we investigated repeated effects of ET-1 and -3 on  $[Ca^{2+}]_i$  transients in OMCT, and typical tracings are demonstrated in Fig. 4. First treatment with  $10^{-6}$  M ET-1 induced transiently  $[Ca^{2+}]_i$  rise and the second treatment with the same concentration of ET-1 did not change the resting  $[Ca^{2+}]_i$ . In a combined experiments of ET-1 with -3, ET-1 or -3 inhibited the  $[Ca^{2+}]_i$  subsequent increase by ET-3 or ET-1, respectively. Both agents evoked similar  $[Ca^{2+}]_i$  transients by either alone.

To clarify the kinds of endothelin receptors in OMCT, we investigated antagonistic effects of BQ-123Na, which is  $ET_A$  receptor antagonist ( $IC_{50}$ :22 nM in aorta) relatively having a weak antagonistic effect to  $ET_B$  receptor ( $IC_{50}$ :18  $\mu$ M in cerebellum). In isolated OMCT, Fig. 5 showed that  $10^{-7}$  M ET-1- and ET-3-induced  $[Ca^{2+}]_i$  were slightly inhibited but significant by the pretreatment with  $10^{-4}$  M BQ-123Na for 3 min ( $163.6 \pm 21.5\%$  to  $231.7 \pm 32.7\%$  for ET-1 and  $210.0 \pm 22.0$  to  $314.0 \pm 38.3$  for ET-3).

In order to further characterize specific receptors for ET-3 in OMCT, radioligand binding experiments were performed using [ $^{125}$ I] ET-3. Nonspecific binding was defined by the coincubation with  $10^{-7}$  M unlabeled ET-3. The binding study as well as  $[Ca^{2+}]_i$  determination, was done at 25°C. Ligand binding reached a plateau at 60 min, specific bindings became greater with increasing concentrations of [ $^{125}$ I] ET-3 in the presence of excessive unlabeled ET-3 ( $10^{-7}$  M) (data not shown). Competitive inhibitory experiments were performed with 200 pM [ $^{125}$ I] ET-3 and  $10^{-7}$  M unlabeled peptides such as ET-1, -2, -3, angiotensin II and vasopressin in OMCT (Fig. 6). Unlabeled ET-1, -2 and -3 at  $10^{-7}$  M inhibited [ $^{125}$ I] ET-3 binding by 86.9, 86.7 and 86.2% ( $p < 0.01$ ), respectively. The vasoconstrictive peptidyl hormones failed to inhibit the ET-3 bindings.

## DISCUSSION

Endothelin-induced transient  $[Ca^{2+}]_i$  increase in

blood vessel, smooth muscle and renal epithelial cells has been reported previously (Vogel et al, 1997, Ankorina-Stark et al, 1997, Marsden et al, 1989, Naruse et al, 1991). Those investigations were carried out using ET-1 and ET-2. According to these studies, endothelin had most potent vasoconstrictive effect among the well-known vasoactive peptidyl agents. Endothelin-1 stimulated the metabolism of inositol phosphates and induced the mobilization of  $[Ca^{2+}]_i$  in vascular smooth muscle, cultured rat medullary interstitial cell and mouse renal epithelial cells. The present findings clearly demonstrate target cells of endothelins within the kidney.

Endothelin-3 induced  $[Ca^{2+}]_i$  transient in Gln showed biphasic, a rapid transient peak and a long sustained phase. Since usage of TMB-8 (Chiou et al, 1975) and verapamil (Karaki et al, 1991) partly attenuated the initial peak height of  $[Ca^{2+}]_i$  transients of a rapid phase and a long sustained phase induced by ET-3 in isolated Gln and OMCT. These results strongly suggested that ET-3-induced transient  $[Ca^{2+}]_i$  increase is mainly from intracellular calcium stores. The sustained phase of  $[Ca^{2+}]_i$  transient occurs largely by  $Ca^{2+}$  influx through plasma membranes. Our data well agreed with many investigation, suggesting that endothelin at high concentrations may raise  $[Ca^{2+}]_i$  through release of  $Ca^{2+}$  from intracellular stores, probably mediated by inositol 1,4,5-triphosphate production particularly (Badr et al, 1989, Mitsuhashi et al, 1989) and may do so through increased  $Ca^{2+}$  influx across plasma membranes, which may or may not be sensitive to  $Ca^{2+}$ -channel blockers (Pang et al, 1989, Watanabe et al, 1989).

The ET-1 and -2 increased  $[Ca^{2+}]_i$  in a dose-dependent manner  $10^{-10}$  to  $10^{-6}$  M. But ET-3-induced  $[Ca^{2+}]_i$  rise began at  $10^{-12}$  M to  $10^{-6}$  M. And data from experiments of repetition and desensitization showed same tendency of ET-1- and -3-induced  $[Ca^{2+}]_i$  in OMCT. BQ-123Na (Ihara et al, 1991) significantly inhibit ET-1- and ET-3-induced  $[Ca^{2+}]_i$  increase in OMCT. These meant that distributed receptors in OMCT were  $ET_B$ -type receptors.

Sarafotoxins S6 b (SRTX) is a group of 21-residue isocardiotoxic peptides, isolated from the venom of the snake *Artactaspis engaddensis*, which is rich in cysteine and shows a high sequence homology with endothelin (Kloog et al, 1988, Sokolovsky 1991). In preliminary experiments, distribution of SRTX-induced  $[Ca^{2+}]_i$  transients in isolated rat single

nephrons were similar to ET-1 (data were not shown).

Chizuko et al, (1989) reported autoradiographic distribution in rat tissues of binding sites for endothelin. According to their results,  $[^{125}I]$ endothelin binding sites are distributed in heart ventricle, kidney, lung, intestine, adrenal gland and brain. In kidney, radiolabelled ET-1 receptor in Glm, cortex, inner medulla and renal papilla (Davenport et al, 1989), but distribution of ET-3 binding site in kidney was obscure still now. Therefore, distribution of ET-3 binding was performed with measurement of  $[Ca^{2+}]_i$ . From  $[^{125}I]$ ET-3 binding and competitive inhibitory experiments, the receptor in OMCT was cleared to be  $ET_B$ .

In conclusion, ETs increase  $[Ca^{2+}]_i$  in Glm, CCT and OMCT. According to the antagonist and binding experiments, endothelin receptors existing in renal epithelial cell were  $ET_B$  subtype.

## REFERENCES

- Ankorina-Stark I, Haxelmans S, Schlatter E. Functional evidence for the regulation of cytosolic  $Ca^{2+}$  activity via  $V_{1A}$ -receptors and beta-adrenoceptors in rat CCD. *Cell Calcium* 21: 163–171, 1997
- Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. *Nature(Lond)* 348: 730–732, 1990
- Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, Glomerular and renal vascular responses to endothelin in the rat kidney. *J Clin Invest* 83: 336–342, 1989
- Butlen D, Vadrot S, Roseau S, Morel F. Insulin receptors along the rat nephron:  $[^{125}I]$  insulin binding in micro-dissected glomeruli and tubules. *Pflugers Arch.* 412: 604–612, 1988
- Cha SH, Jung KY, Endou H. Effect of  $P_{2Y}$ -purinoceptor stimulation on renal gluconeogenesis in rats. *Biochem Biophys Res Commun* 211: 454–461, 1995
- Chiou CY, Malago MH. Studies on the mechanism of action of a new  $Ca^{2+}$  antagonist, 8-(N,N-diethylamino) octyl-3, 4, 5-trimethoxy-benzoate hydrochloride in smooth and skeletal muscles. *Br J Pharmacol* 53: 279–28, 1975
- Chizuko K, Imai M, Hirata Y, Yanagisawa M, Masaki T. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? *Am J Physiol* 256: R858–R866, 1989
- Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ. Autoradiographical localization of binding sites for porcine  $[^{125}I]$ endothelin-1 in humans, pigs, and rats: functional relevance in humans. *J Cardiovasc Pharmacol* 13(suppl.5): S166–S170, 1989
- Giaid A, Gibson SJ, Ibrahim NBN, Legon S, Bloon SR, Yanagisawa M, Masaki T, Vardell IM, Polak JM. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. *Proc Natl Acad Sci U.S.A.* 86: 7634–7638, 1989
- Gryniewicz G, Poenie M, Tsien RY. A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties. *J Biol Chem* 260: 3440–3450, 1985
- Ihara M, Fukuroda T, Saeki T, Nishikibe M, Kojiri K, Suda H, Yano M. An endothelin receptor( $ET_A$ ) antagonist isolated from streptomyces misakiensis. *Biochem Biophys Res Commun* 178: 132–137, 1991
- Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci U.S.A.* 86: 2863–2867, 1989
- Jung KY, Endou H. Mercury chloride as a possible phospholipase C activator: effect on angiotensin II-induced  $[Ca^{++}]_i$  transient in the rat early proximal tubule. *Biochem Biophys Res Commun* 173: 606–613, 1990
- Jung KY, Uchida S, Endou H. Nephrotoxicity assessment by measuring cellular ATP content. 1. Substrate specificities in the maintenance of ATP content in isolated rat nephron segments. *Toxicol Appl Pharmacol* 100: 369–382, 1989
- Karaki H, Sato K, Ozaki H. Different effects of verapamil on cytosolic  $Ca^{2+}$  and contraction in norepinephrine-stimulated vascular smooth muscle. *Jpn J Pharmacol* 55: 35–42, 1991
- King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. *Am J Physiol* 256: F1051–F1058, 1989
- Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. *Nature(Lond)* 242: 268–270, 1988
- Kriz W, Bankir L. A standard nomenclature for structures of the kidney. The renal commission of the international union of physiological science (IUPS) *Kidney Int* 33: 1–7, 1988
- Marsden PA, Danthuluri NR, Brenner GM, Ballermann BJ, Brock TA. Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization. *Biochem Biophys Res Commun* 158: 86–93, 1989
- Martin ER, Brenner BM, Ballermann BJ. Heterogeneity

- of cell surface endothelin receptors. *J Biol Chem* 265: 14044–14049, 1990
- Masaki T. The discovery, the present state, and the future prospects of endothelin. *J Cardiovasc Pharmacol* 13(suppl 5): S1–S4, 1989
- Mitsuhashi T, Morris RC, Ives HE. Endothelin-induced increases in vascular smooth muscle  $Ca^{2+}$  do not depend on dihydropyridine-sensitive  $Ca^{2+}$ . *J Clin Invest* 84: 635–639, 1989
- Naruse M, Uchida S, Ogata E, Kurokawa K. Endothelin 1 increases cell calcium in mouse collecting tubule cells. *Am J Physiol* 261: F720–725, 1991
- Ogawa Y, Nakao K, Arai H, Nakagawa O, Hosoda K, Suga S, Nakanishi S. Molecular cloning of a non-isopeptide-selective human endothelin receptor. *Biochem Biophys Res Commun* 178: 248–255, 1991
- Pang DC, Hohns A, Patterson K, Botelho LHP, Rubanyi GM. Endothelin-1 stimulates phosphatidylinositol hydrolysis and calcium uptake in isolated canine coronary arteries. *J Cardiovasc Pharmacol* 13(suppl.5): S75–S79, 1989
- Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. *Nature (Lond)* 348: 732–735, 1990
- Samson WK, Skala KD, Alexander BD, Huang FLS. Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro. *Biochem Biophys Res Commun* 169: 737–743, 1990
- Sokolovsky M. Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling. *TIBS* 16: 261–265, 1991
- Sugiura M, Inagami T, Hare GMT, Johns JA. Endothelin action: inhibition by a protein kinase C inhibitor and involvement of phosphoinositols. *Biochem Biophys Res Commun* 158: 170–176, 1989
- Tomobe Y, Miyauchi T, Saito A, Yanagisawa M, Kimura S, Goto K, Masaki T. Effects of endothelin on the renal artery from spontaneously hypertensive and wistar kyoto rats. *Eur J Pharmacol* 152: 373–374, 1988
- Totsune K, Mouri T, Takahashi K, Ohneda M, Sone M, Furuta T, Saito T, Yoshinaga K. Immunoreactive endothelin (IR-ET) in plasma of hemodialysis patients. *Kidney Int* 35: 321, 1989
- Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkmann W, Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. *Am J Hypertens* 10: 289–296, 1997
- Watanabe T, Kusumoto K, Kitayoshi T, Shimamoto N. Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of L-type calcium channels. *J Cardiovasc Pharmacol* 13(suppl. 5): S108–S111, 1989
- Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye SI, Nakajima K, Watanabe TX, Sakakibara S, Goto K, Masaki T. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. *Proc Natl Acad Sci U.S.A.* 85: 6964–6967, 1988
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature(Lond)* 332: 411–415, 1988
- Yoshimi H, Hirata Y, Fukuda Y, Kawano Y, Emori T, Kuramochi M, Omae T, Marumo F. Regional distribution of immunoreactive endothelin in rats. *Peptides* 10: 805–808, 1989
- Yoshizawa T, Shinmi O, Giaid A, Yanagisawa M, Gibson SJ, Kimura S, Uchiyama, Polak JM, Masaki T, Kanazawa I. Endothelin: a novel peptide in the posterior pituitary system. *Science* 247: 462–464, 1990
- Zeidel ML, Brady HR, Kone BC, Gullans SR, Brenner BM. Endothelin, a peptide inhibitor of  $Na^+K^+$ -ATPase in intact renal tubular epithelial cells. *Am J Physiol* 257: C1101–C1107, 1989
-